Follow-up of patients with SARS-CoV2-endothelial dysfunction
Summary of the idea:
One abnormality observed in patients with COVID-19 is thrombosis with an incidence of 25%. The causes of cardiovascular complications in patients with COVID-19 are not known, but evidence suggests that endothelial damage caused by the virus may be responsible for this high incidence. The quantification, functionality and metabolic profile of endothelial cells in patients who have undergone COVID-19 will allow us to predict the degree of endothelial dysfunction and improve treatment.
Objectives, impact and proposed solution:
- To determine the prevalence of SARS-CoV-2-induced lung sequelae after severe pneumonia in the province of Girona.
- Establish the best strategy for monitoring and early identification of those cases that develop pulmonary fibrosis as a result of this SARS-CoV-2 injury in the lung.
- To observe the quality of life of patients after SARS-CoV-2 infection.
- Assess whether a functional and metabolic profile of endothelial progenitor cells is able to predict and evolutionarily identify endothelial-associated complications that occur in patients who have undergone COVID-19, and more specifically those that are related to a coagulopathy that evokes the patient to suffer a pulmonary thromboembolism.
